alglucerase

{{Short description|Pharmaceutical drug}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 477317276

| IUPAC_name = Human beta-glucocerebrosidase

| image =

| tradename =

| Drugs.com = {{drugs.com|monograph|alglucerase}}

| MedlinePlus = a692001

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life = 3.6–10.4 min

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 143003-46-7

| ATC_prefix = A16

| ATC_suffix = AB01

| ATC_supplemental =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB00088

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 27T56C7KK0

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D09675

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201633

| C=2532 | H=3854 | N=672 | O=711 | S=16

}}

Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.{{cite journal | vauthors = Deegan PB, Cox TM | title = Imiglucerase in the treatment of Gaucher disease: a history and perspective | journal = Drug Design, Development and Therapy | volume = 6 | pages = 81–106 | year = 2012 | pmid = 22563238 | pmc = 3340106 | doi = 10.2147/DDDT.S14395 | doi-access = free }}

Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue. It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug approved as an enzyme replacement therapy.

It was approved by the FDA in 1991.World Health Organization. [https://web.archive.org/web/20051108094021/http://whqlibdoc.who.int/druginfo/DRUG_INFO_5_3_1991_p122-125.pdf Regulatory Matters] WHO Drug Information 5:3 1991. p 123 It has been withdrawn from the marketAetna. Last reviewed 8 August 2014 [http://www.aetna.com/cpb/medical/data/400_499/0442.html Clinical Policy Bulletin Number: 0442: Enzyme-replacement Therapy for Lysosomal Storage Disorders]FDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. [https://web.archive.org/web/20120927210833/http://www.fda.gov/downloads/Drugs/InformationOnDrugs/UCM300963.pdf Additions/Deletions for Prescription Drug Product List] due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture (see imiglucerase).